cabotegravir/rilpivirine long-acting


DHHS recommendation not yet established
Long-Acting Regimen

Standard Dose

Clinical trials of this investigational regimen used a long-acting cabotegravir injection of 400 mg plus 600 mg long-acting rilpivirine injection every month. There was a month-long oral lead-in using 30 mg cabotegravir plus 25 mg rilpivirine prior to initiating injections. Oral medication is also expected to be used as “bridging” if shots cannot be obtained on time. The cabotegravir tablet may not otherwise be available on the market. This regimen consists of the NNRTI rilpivirine with the new INSTI cabotegravir. Oral rilpivirine must be taken with food; the injectable does not need to be taken with food. After the month-long oral lead-in, two loading doses are administered consisting of two 3 mL injections of cabotegravir plus rilpivirine. Maintenance dose consists of two 2 mL injections of cabotegravir plus rilpivirine monthly.

See Edurant; cabotegravir is not yet available

See package insert when available for more complete information on potential side effects and interactions.


ViiV Healthcare
(877) 844-8872


Not yet established.

Potential Side Effects and Toxicity

Potential Drug Interactions

More Information

Doctor Comments

Activist Comments